660 related articles for article (PubMed ID: 28085503)
1. Dupilumab for the treatment of asthma.
Santini G; Mores N; Malerba M; Mondino C; Anzivino R; Macis G; Montuschi P
Expert Opin Investig Drugs; 2017 Mar; 26(3):357-366. PubMed ID: 28085503
[TBL] [Abstract][Full Text] [Related]
2. Dupilumab in persistent asthma with elevated eosinophil levels.
Wenzel S; Ford L; Pearlman D; Spector S; Sher L; Skobieranda F; Wang L; Kirkesseli S; Rocklin R; Bock B; Hamilton J; Ming JE; Radin A; Stahl N; Yancopoulos GD; Graham N; Pirozzi G
N Engl J Med; 2013 Jun; 368(26):2455-66. PubMed ID: 23688323
[TBL] [Abstract][Full Text] [Related]
3. Dupilumab for the treatment of asthma.
Pelaia C; Vatrella A; Gallelli L; Terracciano R; Navalesi P; Maselli R; Pelaia G
Expert Opin Biol Ther; 2017 Dec; 17(12):1565-1572. PubMed ID: 28990423
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies for the treatment of refractory asthma.
Hambly N; Nair P
Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
Castro M; Corren J; Pavord ID; Maspero J; Wenzel S; Rabe KF; Busse WW; Ford L; Sher L; FitzGerald JM; Katelaris C; Tohda Y; Zhang B; Staudinger H; Pirozzi G; Amin N; Ruddy M; Akinlade B; Khan A; Chao J; Martincova R; Graham NMH; Hamilton JD; Swanson BN; Stahl N; Yancopoulos GD; Teper A
N Engl J Med; 2018 Jun; 378(26):2486-2496. PubMed ID: 29782217
[TBL] [Abstract][Full Text] [Related]
6. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
[TBL] [Abstract][Full Text] [Related]
7. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma.
Busse WW; Maspero JF; Rabe KF; Papi A; Wenzel SE; Ford LB; Pavord ID; Zhang B; Staudinger H; Pirozzi G; Amin N; Akinlade B; Eckert L; Chao J; Graham NMH; Teper A
Adv Ther; 2018 May; 35(5):737-748. PubMed ID: 29725983
[TBL] [Abstract][Full Text] [Related]
8. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
[TBL] [Abstract][Full Text] [Related]
9. [Dupilumab : a new treatment for severe T2 high asthma].
Louis R; Sabbe M; Bougard N; Frix AN; Schleich F
Rev Med Liege; 2024 Apr; 79(4):255-259. PubMed ID: 38602214
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.
Rabe KF; Nair P; Brusselle G; Maspero JF; Castro M; Sher L; Zhu H; Hamilton JD; Swanson BN; Khan A; Chao J; Staudinger H; Pirozzi G; Antoni C; Amin N; Ruddy M; Akinlade B; Graham NMH; Stahl N; Yancopoulos GD; Teper A
N Engl J Med; 2018 Jun; 378(26):2475-2485. PubMed ID: 29782224
[TBL] [Abstract][Full Text] [Related]
12. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
[TBL] [Abstract][Full Text] [Related]
14. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab for the treatment of atopic dermatitis: A clinical trial review.
McGregor S; Farhangian ME; Feldman SR
Expert Opin Biol Ther; 2015; 15(11):1657-60. PubMed ID: 26428945
[TBL] [Abstract][Full Text] [Related]
16. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
17. A drug safety review of treating eosinophilic asthma with monoclonal antibodies.
Mitchell P; Leigh R
Expert Opin Drug Saf; 2019 Dec; 18(12):1161-1170. PubMed ID: 31594389
[No Abstract] [Full Text] [Related]
18. Monoclonal antibodies in severe asthma: is it worth it?
Calzetta L; Matera MG; Rogliani P
Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):517-520. PubMed ID: 31104515
[No Abstract] [Full Text] [Related]
19. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis.
Edris A; De Feyter S; Maes T; Joos G; Lahousse L
Respir Res; 2019 Aug; 20(1):179. PubMed ID: 31395084
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-4/interleukin-13 versus interleukin-5: a comparison of molecular targets in biologic therapy for the treatment of severe asthma.
Wu AY; Sur S; Grant JA; Tripple JW
Curr Opin Allergy Clin Immunol; 2019 Feb; 19(1):30-37. PubMed ID: 30407206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]